Drug
Cenegermin clinical trials
Also written Oxervate®.
Keep track of what changes. Save the cenegermin studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
8 studies that test it; most in 2022 (3)
| Year | Studies |
|---|---|
| 2020 | 1 |
| 2022 | 3 |
| 2023 | 1 |
| 2024 | 1 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 6 · Other 2
Dompé Farmaceutici S.p.A (6) · Toyos Clinic (1) · Tufts Medical Center (1)
Studies
Open first, then newest update. How each study uses cenegermin is read from its arms, and is right about nine times in ten.
Testing it · 8
- An Efficacy and Safety Study of Cenegermin Ophthalmic Solution Compared With Vehicle in the Treatment of PCEDRecruitingPhase 3Dompé Farmaceutici S.p.ANCT07519902Written as Cenegermin
- Efficacy and Safety of Intranasal Cenegermin in Adult Participants With Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION)RecruitingPhase 3Dompé Farmaceutici S.p.ANCT07453888Written as Cenegermin
- Study to Evaluate Safety and Efficacy of Cenegermin (Oxervate®) vs Vehicle in Severe Sjogren's Dry Eye DiseaseCompletedPhase 3Dompé Farmaceutici S.p.ANCT05136170Written as Cenegermin
- Study to Evaluate OXERVATE® in Patients With Stage 1 Neurotrophic KeratitisCompletedPhase 4Dompé Farmaceutici S.p.ANCT04485546Written as cenegermin-bkbj
- DOMPE -MT Neurotrophic KeratitisActive, not recruitingPhase 4Toyos ClinicNCT06947850Written as Cenegermin Ophthalmic Solution [Oxervate]
- Open-label Trial to Evaluate Efficacy and Safety of rhNGF on Corneal Thickness Via AS-OCT in Neurotrophic KeratitisWithdrawnPhase 4Dompé Farmaceutici S.p.ANCT06411145Written as OXERVATE® 0.002%
- Safety and Efficacy Study on Cenegermin (Oxervate®) vs Vehicle in Severe Sjogren's Dry Eye Disease (PROTEGO-1 Study)CompletedPhase 3Dompé Farmaceutici S.p.ANCT05133180Written as Oxervate
- NGF Treatment for Patients With Neuropathic Corneal PainWithdrawnPhase 1Tufts Medical CenterNCT05700864Written as Cenegermin-Bkbj
As the comparator · 1 — what is tested is compared with cenegermin
Codes
What other systems call cenegermin · ClinicalTrials.gg INT001179
- MeSH (NLM) C000647429cenegerminConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) B6E7K36KT8CENEGERMINConfirmed FDA, NLM
- RxNorm 2104332One source FDA
- NCI Thesaurus C171893CenegerminOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000647429 | cenegermin | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | B6E7K36KT8 | CENEGERMIN | Confirmed FDA, NLM |
| RxNorm | 2104332 | — | One source FDA |
| NCI Thesaurus | C171893 | Cenegermin | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.